Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 28, 2019; 25(8): 1002-1011
Published online Feb 28, 2019. doi: 10.3748/wjg.v25.i8.1002
Published online Feb 28, 2019. doi: 10.3748/wjg.v25.i8.1002
Table 1 Demographic and clinical characteristics of patients
Characteristic | Non-pathway group (n = 467) | Cinical pathway group (n = 2196) | P value |
Age, yr (median, range) | 64 (52-75) | 63 (51-75) | 0.405 |
Female, n (%) | 235 (50.32) | 1093 (49.77) | 0.829 |
Medical insurance, n (%) | 217 (46.47) | 945 (43.03) | 0.174 |
Health behavior, n (%) | |||
Smoking | 57 (12.21) | 260 (11.84) | 0.825 |
Alcohol use | 36 (7.71) | 164 (7.47) | 0.858 |
Comorbidity, n (%) | |||
Hypertension | 155 (33.19) | 703 (32.01) | 0.621 |
Diabetes | 68 (14.56) | 292 (13.30) | 0.468 |
COPD | 11 (2.36) | 54 (2.46) | 0.895 |
Myocardial infarction | 0 | 6 (0.27) | 0.258 |
Cholangitis | 74 (15.85) | 271 (12.34) | 0.041a |
Cholecystolithiasis | 188 (40.26) | 780 (35.52) | 0.053 |
JPD | 1 (0.21) | 10 (0.46) | 0.460 |
CBD stone number ≥ 5, n (%) | 201 (43.04) | 1173 (53.42) | < 0.001a |
Maximum diameter of stones, cm (median, range) | 0.8 (0.6-1.2) | 0.9 (0.6-1.2) | 0.949 |
Laboratory test (median, range) | |||
Temperature (°C), n = 359/2113 | 36.5 (36.3-36.8) | 36.5 (36.3-36.8) | 0.855 |
WBC count, n = 370/1451 | 6.0 (4.7-9.2) | 5.7 (4.6-7.6) | 0.005a |
Direct bilirubin level, n = 363/1439 | 12.2 (5.6-44.2) | 10.7 (4.8-37.2) | 0.210 |
Total bilirubin level, n = 363/1439 | 22.6 (12.7-57.6) | 21.2 (12.5-51.9) | 0.628 |
AST, n = 363/1440 | 47.9 (22.8-104.5) | 45.4 (23.5-104.8) | 0.842 |
GGT, n = 363/1439 | 257.4 (115.3-492.4) | 265.1 (109.9-519.4) | 0.918 |
ALP, n = 363/1439 | 161.7 (99.9-283.3) | 154.9 (97.4-259.3) | 0.536 |
ALT, n = 364/1443 | 85.1 (29.6-203.2) | 89.0 (32.0-206.9) | 0.946 |
Cr, n = 361/1431 | 62.0 (52.0-74.0) | 62.0 (2.0-73.0) | 0.966 |
Table 2 Comparison of length of hospital stay, clinical outcomes, hospital charges, and drug use between the non-pathway and clinical pathway groups
Characteristic | Non-pathway group (n = 467) | Cinical pathway group (n = 2196) | P value |
Length of total hospital stay (median, range) | 8 (6-11) | 7 (5-9) | < 0.001a |
Pre-operative length of stay | 2 (1-4) | 2 (1-3) | 0.451 |
Readmission, n (%) | 34 (7.28) | 173 (7.88) | 0.661 |
Clinical outcomes, n (%) | 0.115 | ||
Recovered | 223 (47.75) | 1146 (52.19) | |
Improved | 236 (50.54) | 1028 (46.81) | |
Not improved | 8 (1.71) | 22 (1) | |
Died | 0 | 0 | |
Charges of hospitalization (CNY), (median, range) n = 467/2183 | 21508.3 (17150.6-30045.8) | 18362.9 (15665.8-22895.2) | < 0.001a |
Charges of medication, n = 459/2153 | 6620.6 (3429.4-12239.7) | 4900.6 (3172.4-8186.0) | < 0.001a |
Charges of operation, n = 458/2151 | 5741.0 (4519.2-7324.0) | 5455.2 (2670.0-6964.0) | < 0.001a |
Charges of nursing, n = 454/2133 | 188.0 (115.0-288.0) | 120.0 (74.0-211.0) | < 0.001a |
Charges of materials, n = 409/1540 | 7916.4 (6696.0-10552.6) | 6985.5 (6135.1-8224.7) | < 0.001a |
Charges of examination, n = 459/2153 | 2698.0 (2224.5-3799.5) | 2463.5 (2134.5-3105.5) | < 0.001a |
Antibiotic use, n (%) | 260/430 (60.47) | 832/1737 (47.90) | < 0.001a |
Antibiotic usage duration (d) (median, range), n = 260/832 | 12 (8.0-18.5) | 11 (7.0-17.0) | 0.004a |
Three line antibiotic use, n (%) | 51/430 (11.86) | 149/1737 (8.58) | 0.035a |
Secondary surgery, n (%) | 69 (14.78) | 372 (16.94) | 0.253 |
Table 3 Comparison of postoperative complication rates between the non-pathway and clinical pathway groups
Characteristic | Non-pathway group (n = 467) | Cinical pathway group (n = 2196) | P value |
Total, n (%) | 125 (26.77) | 316 (14.39) | < 0.001a |
Acute pancreatitis | 113 (24.20) | 298 (13.57) | < 0.001a |
Gallbladder perforation | 1 (0.21) | 1 (0.05) | 0.227 |
Gastrointestinal hemorrhage | 0 | 2 (0.09) | 0.514 |
Biliary tract infection | 2 (0.43) | 4 (0.18) | 0.308 |
Liver abscess | 10 (2.14) | 11 (0.50) | < 0.001a |
Table 4 Univariate logistic regression analysis of outcomes
Characteristic | Non-pathway group (n = 467) | Cinical pathway group (n = 2196) | OR (95%CI) | P value | |
Length of total hospital stay (median, range) | 8 (6-11) | 7 (5-9) | < 0.001a | ||
Pre-operative length of stay | 2 (1-4) | 2 (1-3) | 0.078 | ||
Readmission, n (%) | 34 (7.28) | 173 (7.88) | 1.09 (0.74, 1.60) | 0.661 | |
Clinical outcomes, n (%) | 1.21 (0.99, 1.47) | 0.064 | |||
Charges of hospitalization (CNY) (median, range) | 21508.3 (17150.6-30045.8) | 18362.9 (15665.8-22895.2) | < 0.001a | ||
Medication | 6620.6 (3429.4-12239.7) | 4900.6 (3172.4-8186.0) | < 0.001a | ||
Operating | 5741.0 (4519.2-7324.0) | 5455.2 (2670.0-6964.0) | < 0.001a | ||
Nursing | 188.0 (115.0-288.0) | 120.0 (74.0-211.0) | < 0.001a | ||
Materials | 7916.4 (6696.0-10552.6) | 6985.5 (6135.1-8224.7) | < 0.001a | ||
Examination | 2698.0 (2224.5-3799.5) | 2463.5 (2134.5-3105.5) | < 0.001a | ||
Antibiotic use, n (%) | 260/430 (60.47) | 832/1737(47.90) | 0.60 (0.49, 0.75) | < 0.001a | |
Antibiotic usage duration (d) (median, range) | 12 (8.0-18.5) | 11 (7.0-17.0) | 0.310 | ||
Three line antibiotic use, n (%) | 51/430 (11.86) | 149/1437 (8.58) | 0.69 | 0.036a | |
Secondary surgery, n (%) | 69 (14.78) | 372 (16.94) | 1.18 | 0.254 | |
Complications | 125 (26.77) | 316 (14.39) | 0.46 (0.36, 0.58) | < 0.001a |
Table 5 Multivariate logistic and linear regression analysis of outcomes
Characteristic | Adjusted OR (95%CI) or coefficients | P value |
Length of total hospital stay | -1.71 (-2.30, -1.12)1 | < 0.001a |
Hospitalization costs | -5572.26 (-6931.48, -4213.03)1 | < 0.001a |
Medication costs | -2760.03 (-3738.96, -1781.11)1 | < 0.001a |
Operating costs | -382.08 (-635.30, -128.85)1 | < 0.001a |
Nursing costs | -138.25 (-195.83, -80.66)1 | < 0.001a |
Materials costs | -1688.35 (-2049.61, -1327.10)1 | < 0.001a |
Examination costs | -138.25 (-195.83, -80.66)1 | < 0.001a |
Three line antibiotic use | 0.89 (0.60, 1.31) | 0.546 |
Antibiotic use, n (%) | 0.72 (0.55, 0.93) | 0.012a |
Complications | 0.44 (0.33, 0.59) | < 0.001a |
- Citation: Zhang W, Wang BY, Du XY, Fang WW, Wu H, Wang L, Zhuge YZ, Zou XP. Big-data analysis: A clinical pathway on endoscopic retrograde cholangiopancreatography for common bile duct stones. World J Gastroenterol 2019; 25(8): 1002-1011
- URL: https://www.wjgnet.com/1007-9327/full/v25/i8/1002.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i8.1002